Episode five closes the chapter with hereditary pancreatic cancer and the family-systems coordination that binds every syndrome together. The gating principle is absolute lifetime risk, not relative risk: surveillance begins above roughly five percent, so STK11, CDKN2A, PRSS1, and familial kindreds qualify on genotype alone while BRCA1, BRCA2, ATM, PALB2, and Lynch enter only with a family-history driver. The treatment side ties platinum and PARP inhibitors back to synthetic lethality in homologous-recombination-deficient tumors. The coordination side names the real failure mode, the carrier whose colonoscopy stays on schedule while gynecologic or urologic surveillance lapses, and the board traps around cascade testing, the GINA insurance gap, and the non-actionable variant of uncertain significance.

Topics covered

Germline genes behind pancreatic cancer
The absolute-risk surveillance threshold
Which carriers qualify on gene alone
Surveillance starting ages and modality
PRSS1 hereditary pancreatitis
Synthetic lethality, platinum, and PARP inhibitors
Multi-organ coordination and cascade testing
Risk-reducing surgery and reproductive counseling
GINA limits and variants of uncertain significance

Key decisions

Gate pancreatic surveillance on absolute lifetime risk above approximately five percent, above which cancer detection outweighs the false positives, procedural complications, and cyst-driven anxiety below it.
Enroll STK11, CDKN2A, PRSS1, and familial pancreatic cancer kindreds on genotype or pedigree alone, but enroll BRCA1, BRCA2, ATM, PALB2, and Lynch carriers only with a first-degree or second-degree relative with pancreatic cancer.
Start surveillance at thirty to thirty-five for STK11, forty for CDKN2A and PRSS1, and fifty for BRCA, ATM, PALB2, and Lynch, or ten years before the earliest family pancreatic cancer, whichever is younger.
Alternate annual EUS and pancreatic-protocol MRI with MRCP because they are complementary, EUS for solid lesions and same-session sampling, MRI for cysts and ductal anatomy without procedural risk.
Offer maintenance olaparib after at least sixteen weeks of platinum-based chemotherapy without progression in germline BRCA metastatic pancreatic cancer, because it roughly doubled progression-free survival and germline panel testing is now standard at diagnosis.
Do not act on a variant of uncertain significance: it does not justify cascade testing or gene-specific surveillance, and the program stays anchored to personal and family history.
Counsel carriers that GINA covers health insurance and employment but not life, disability, or long-term care insurance, and advise obtaining those policies before testing.

For the full chapter with MCQs, tables, and primary-guideline references, visit www.boardpearls.com.

Questions or feedback: hello@boardpearls.com.

(00:00) - Germline genes behind pancreatic cancer
(00:39) - Two mechanistic gene families
(01:42) - The absolute-risk surveillance threshold
(03:50) - Starting ages and surveillance modality
(04:36) - Alternating EUS and MRI
(05:51) - PRSS1 hereditary pancreatitis
(07:03) - Synthetic lethality and PARP inhibitors
(09:56) - Multi-organ coordination and cascade testing
(12:53) - GINA limits and the VUS trap